CXCR2 and metabolic dysfunction-associated steatohepatitis: They reported that combining anti-PD-1 with AZD5069, a CXCR2 inhibitor, led to the reprogramming of TANs to a more proliferative and inflammatory phenotype, increased intra-tumoral XCR1+ DCs and CD8+ T-cell infiltration, and enhanced anti-tumor response in NASH-HCC models (Table 4).